High-throughput biophysical analysis and data visualization of conformational stability of an igg1 monoclonal antibody after deglycosylation

Journal of Pharmaceutical Sciences

Volumn 102, Issue 11, 2013, Pages 3942-3956

  Alsenaidy, Mohammad A ^a   Kim, Jae Hyun ^a   Majumdar, Ranajoy ^a   Weis, David D ^a   Joshi, Sangeeta B ^a   Tolbert, Thomas J ^a   Middaugh, C Russell ^a   Volkin, David B ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Biophysical; Conformation; Formulation; Glycosylation; Monoclonal antibody; Stability; Structure

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY;

ANTIBODY STABILITY; ANTIBODY STRUCTURE; ARTICLE; DEGLYCOSYLATION; DIFFERENTIAL SCANNING CALORIMETRY; ENVIRONMENTAL STRESS; FLUOROMETRY; GLYCOSYLATION; MASS SPECTROMETRY;

BIOPHYSICAL; CONFORMATION; FORMULATION; GLYCOSYLATION; MONOCLONAL ANTIBODY; STABILITY; STRUCTURE;

ANTIBODIES, MONOCLONAL; CALORIMETRY, DIFFERENTIAL SCANNING; CIRCULAR DICHROISM; GLYCOSYLATION; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN G; PROTEIN CONFORMATION; PROTEIN STABILITY; TEMPERATURE;

EID: 84885868713     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23730     Document Type: Article

References (60)

1. Reichert JM. 2012. Marketed therapeutic antibodies compendium. mAbs 4(3):413-415.
2. Nelson AL, Dhimolea E, Reichert JM. 2010. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767-774.
3. Jefferis R. 2009. The antibody paradigm: Present and future development as a scaffold for biopharmaceutical drugs. Biotechnol Genet Eng Rev 26(1):1-41.
4. Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci 96(1):1-26.
5. Jefferis R. 2012. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 526(2):159-166.
6. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. 2007. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25(1):21-50.
7. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M. 2007. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types. Glycobiology 17(1):104-118.
8. Jefferis R. 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8(3):226-234.
9. Jefferis R, Lund J. 2002. Interaction sites on human IgG-Fc for FcγR: Current models. Immunol Lett 82(1-2):57-65.
10. Boyd PN, Lines AC, Patel AK. 1995. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 32(17-18):1311-1318.
11. Radaev S, Sun PD. 2001. Recognition of IgG by Fcγ receptor. J Biol Chem 276(19):16478-16483.
12. Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan J-P, Bayer R. 2012. Production, characterization and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. mAbs 4(4):475-487.
13. Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang Y-MC. 2010. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 28(10):509-516.
14. Liu L, Stadheim A, Hamuro L, Pittman T, Wang W, Zha D, Hochman J, Prueksaritanont T. 2011. Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: A comparative study with CHO produced materials. Biologicals 39(4):205-210.
15. Alessandri L, Ouellette D, Acquah A, Rieser M, LeBlond D, Saltarelli M, Radziejewski C, Fujimori T, Correia I. 2012. Increased serum clearance of oligomannose species present on a human IgG1 molecule. mAbs 4(4):509-520.
16. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. 2011. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 21(7):949-959.
17. Bumbaca D, Boswell C, Fielder P, Khawli L. 2012. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J 14(3):554-558.
18. Chen X, Liu YD, Flynn GC. 2009. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 19(3):240-249.
19. Solá RJ, Griebenow K. 2009. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 98(4):1223-1245.
20. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. 2003. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325(5):979-989.
21. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R. 2000. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: Properties of a series of truncated glycoforms. Mol Immunol 37(12-13): 697-706.
22. Ha S, Ou Y, Vlasak J, Li Y, Wang S, Vo K, Du Y, Mach A, Fang Y, Zhang N. 2011. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. Glycobiology 21(8):1087-1096.
23. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI. 2010. High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 99(4):1707-1720.
24. Wen J, Jiang Y, Narhi L. 2008. Effect of carbohydrate on thermal stability of antibodies. Am Pharm Rev 11:98-104.
25. Ha S, Wang Y, Rustandi RR. 2011. Biochemical and biophysical characterization of humanized IgG1 produced in Pichia pastoris. mAbs 3(5):453-460.
26. Hari SB, Lau H, Razinkov VI, Chen S, Latypov RF. 2010. Acid-induced aggregation of human monoclonal IgG1 and IgG2: Molecular mechanism and the effect of solution composition. Biochemistry 49(43):9328-9338.
27. Liu H, Bulseco G-G, Sun J. 2006. Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. Immunol Lett 106(2):144-153.
28. Raju TS, Scallon BJ. 2006. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem Biophys Res Commun 341(3):797-803.
29. Raju TS, Scallon B. 2007. Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain. Biotechnol Progr 23(4):964-971.
30. Li CH, Narhi LO, Wen J, Dimitrova M, Wen Z-Q, Li J, Pollastrini J, Nguyen X, Tsuruda T, Jiang Y. 2012. Effect of pH, temperature, and salt on the stability of Escherichia coli- and Chinese hamster ovary cell-derived IgG1 Fc. Biochemistry 51(50):10056-10065.
31. Latypov RF, Hogan S, Lau H, Gadgil H, Liu D. 2012. Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. J Biol Chem 287(2):1381-1396.
32. Lu Y, Westland K, Ma Y-h, Gadgil H. 2012. Evaluation of effects of Fc domain high-mannose glycan on antibody stability. J Pharm Sci 101(11):4107-4117.
33. Ghirlando R, Lund J, Goodall M, Jefferis R. 1999. Glycosylation of human IgG-Fc: Influences on structure revealed by differential scanning micro-calorimetry. Immunol Lett 68(1):47-52.
34. Hristodorov D, Fischer R, Joerissen H, Müller-Tiemann B, Apeler H, Linden L. 2013. Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies. Mol Biotechnol 53(3):326-335.
35. Zheng K, Bantog C, Bayer R. 2011. The impact of glycosylation on monoclonal antibody conformation and stability. mAbs 3(6):568-576.
36. Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, Prabakaran P, Veenstra TD, Tarasov SG, Ishima R, Dimitrov DS. 2009. Engineered human antibody constant domains with increased stability. J Biol Chem 284(21):14203-14210.
37. Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G. 2012. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem Biol 7(9):1596-1602.
38. Houde D, Arndt J, Domeier W, Berkowitz S, Engen JR. 2009. Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry. Anal Chem 81(7):2644-2651.
39. Houde D, Peng Y, Berkowitz SA, Engen JR. 2010. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 9(8):1716-1728.
40. Wang X, Kumar S, Buck PM, Singh SK. 2013. Impact of deglycosylation and thermal stress on conformational stability of a full length murine IgG2a monoclonal antibody: Observations from molecular dynamics simulations. Proteins 81(3):443-460.
41. Wu S-J, Luo J, O'Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS, Jacobs SA, Teplyakov A, Gilliland GL, Feng Y. 2010. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Select 23(8):643-651.
42. Middaugh CR, Litman GW. 1987. Atypical glycosylation of an IgG monoclonal cryoimmunoglobulin. J Biol Chem 262(8):3671-3673.
43. Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL. 2011. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J 6(1):38-44.
44. Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL. 2009. Aggregation-prone motifs in human immunoglobulin G. J Mol Biol 391(2):404-413.
45. Manikwar P, Majumdar R, Hickey JM, Thakkar SV, Samra HS, Sathish HA, Bishop SM, Middaugh CR, Weis DD, Volkin DB. 2013. Correlating excipient effects on conformational and storage stability of an IgG1 monoclonal antibody with local dynamics as measured by hydrogen/deuterium-exchange mass spectrometry. J Pharm Sci 102(7):2136-2151.
46. Majumdar R, Manikwar P, Hickey JM, Samra HS, Sathish HA, Bishop SM, Middaugh CR, Volkin DB, Weis DD. 2013. Effects of salts from the Hofmeister series on the conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal antibody. Biochemistry 52(19):3376-3389.
47. Chirino AJ, Mire-Sluis A. 2004. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 22(11):1383-1391.
48. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. 2011. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29(4): 310-312.
49. Lubiniecki A, Volkin DB, Federici M, Bond MD, Nedved ML, Hendricks L, Mehndiratta P, Bruner M, Burman S, DalMonte P, Kline J, Ni A, Panek ME, Pikounis B, Powers G, Vafa O, Siegel R. 2011. Comparability assessments of process and product changes made during development of two different monoclonal antibodies. Biologicals 39(1):9-22.
50. Schenerman MA, Hope JN, Kletke C, Singh JK, Kimura R, Tsao EI, Folena-Wasserman G. 1999. Comparability testing of a humanized monoclonal antibody (Synagis®) to support cell line stability, process validation, and scale-up for manufacturing. Biologicals 27(3):203-215.
51. Jiang X-R, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. 2011. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 10(2):101-111.
52. Federici M, Lubiniecki A, Manikwar P, Volkin DB. 2013. Analytical lessons learned from selected therapeutic protein drug comparability studies. Biologicals 41(3):131-147.
53. Bhambhani A, Kissmann JM, Joshi SB, Volkin DB, Kashi RS, Middaugh CR. 2012. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions. J Pharm Sci 101(3):1120-1135.
54. Cheng W, Joshi SB, He F, Brems DN, He B, Kerwin BA, Volkin DB, Middaugh CR. 2012. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: Conformational stability and kinetic aggregation measurements. J Pharm Sci 101(5):1701-1720.
55. Hu L, Joshi SB, Andra KK, Thakkar SV, Volkin DB, Bann JG, Middaugh CR. 2012. Comparison of the structural stability and dynamic properties of recombinant anthrax protective antigen and its 2-fluorohistidine-labeled analogue. J Pharm Sci 101(11):4118-4128.
56. Alsenaidy MA, Wang T, Kim JH, Joshi SB, Lee J, Blaber M, Volkin DB, Middaugh CR. 2012. An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1. Protein Sci 21(3):418-432.
57. Kim JH, Iyer V, Joshi SB, Volkin DB, Middaugh CR. 2012. Improved data visualization techniques for analyzing macromolecule structural changes. Protein Sci 21(10):1540-1553.
58. Maddux NR, Rosen IT, Hu L, Olsen CM, Volkin DB, Middaugh CR. 2012. An improved methodology for multidimensional high-throughput preformulation characterization of protein conformational stability. J Pharm Sci 101(6):2017-2024.
59. Iyer V, Maddux N, Hu L, Cheng W, Youssef AK, Winter G, Joshi SB, Volkin DB, Middaugh CR. 2013. Comparative signature diagrams to evaluate biophysical data for differences in protein structure across various formulations. J Pharm Sci 102(1):43-51.
60. Shi S, Liu J, Joshi SB, Krasnoperov V, Gill P, Middaugh CR, Volkin DB. 2012. Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. J Pharm Sci 101(6):1969-1984.